Market Overview - The Shanghai Composite Index closed at 3602.13 points, above the five-day moving average, with a gain of 0.53% [1] - The total trading volume of A-shares reached 10185.93 billion yuan [1] Stocks Performance - A total of 1060 A-shares have prices that surpassed the five-day moving average [1] - Notable stocks with significant deviation rates include: - Nanjing Julong (11.66%) - Dongxin He Ping (7.92%) - Zhongheng Group (7.73%) [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the five-day moving average: - Nanjing Julong: 13.63% increase, trading volume 21.00% [1] - Dongxin He Ping: 10.00% increase, trading volume 20.47% [1] - Zhongheng Group: 9.85% increase, trading volume 1.31% [1] - Jianlong Micro-Nano: 9.14% increase, trading volume 3.44% [1] - San Chao New Materials: 9.88% increase, trading volume 26.05% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Boshang Optoelectronics: 10.52% increase, trading volume 25.60% [1] - Astone Creation: 11.98% increase, trading volume 28.04% [1] - Shanghai Shifa Development: 10.06% increase, trading volume 2.46% [1] - Fuheng New Materials: 7.19% increase, trading volume 11.34% [1] - Dazhu Digital Control: 8.32% increase, trading volume 17.89% [1]

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF managed by Jiashi, with significant trading activity and inflows [2] - As of August 4, the Kexin Pharmaceutical ETF Jiashi has seen a weekly average trading volume of 58.54 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 12.30 million yuan over the past two weeks, also leading among comparable funds [2] - The fund's net asset value has risen by 50.01% over the past year, placing it in the top 15.64% of index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - The biopharmaceutical industry is expected to stabilize and grow throughout 2025, supported by favorable policies for innovative drug development and medical equipment updates [5] - The transition to the 2.0 era of innovative drugs in China is marked by a qualitative improvement, with domestic new drugs expected to participate deeply in the global market over the next decade [4]

成大生物最新价较发行价折价71.07%，天宜新材最新价较发行价折价66.00%，康希诺最新价较发行价 折价61.65%，中科微至最新价较发行价折价61.65%，金迪克最新价较发行价折价57.21%。（数据宝） 科创板股破发幅度排名 科创板股最新收盘价较发行价平均溢价114.49%，其中，143股出现破发。 证券时报·数据宝统计显示，已上市的589只科创板股中，最新收盘价较发行价平均溢价114.49%，其 中，收盘价较发行价溢价的有445只，溢价幅度最高的是上纬新材，最新收盘价较发行价溢价 3686.03%，热景生物、安集科技、百利天恒等紧随其后，分别溢价1090.17%、1085.87%、1079.76%。 最新收盘价较发行价出现折价的有143只，也即是破发。 破发幅度最大的是万润新能，最新价较发行价折价79.04%，该股2022年9月29日上市，发行价为299.88 元，发行市盈率为75.25倍，行业平均市盈率为19.21倍，公司主要从事锂电池正极材料的研发、生产和 销售。 其次是ST帕瓦，该股2022年9月19日上市，最新价较发行价折价76.75%，发行价为51.88元，发行市盈率 为93.68倍，行业平 ...

疫苗股继续活跃，其中，康希诺AH股午后拉升，A股一度涨超16%报82.48元，股价创2023年12月以来新高；H股拉升一度涨近14%报48.55港元，股价创 2023年3月以来新高。 随着确诊病例数量的增加，以及世界卫生组织专家发出的警报，市场对相关疫苗的需求预期显著增强，刺激疫苗股获资金追捧。 消息面上，基孔肯雅热在广东佛山市的爆发继续成为市场关注的焦点。据广东省疾控局消息，2025年7月20日0时至7月26日24时，广东省新增报告2940例 基孔肯雅热本地病例，未报告重症和死亡病例。病例分布在佛山2882例，广州22例，中山18例，东莞、珠海、河源各3例，江门、阳江、肇庆各2例，清 远、深圳、湛江各1例。 ...

Core Insights - The average premium of the latest closing prices of listed Sci-Tech Innovation Board stocks compared to their issue prices is 111.81%, with 153 stocks experiencing a decline in value [1][2][3] Group 1: Premium and Discount Analysis - Among the 589 listed Sci-Tech Innovation Board stocks, 436 stocks have a closing price higher than their issue price, while 153 stocks have fallen below their issue price [1][2] - The stock with the highest premium is Shuangwei New Materials, with a closing price that is 3361.58% higher than its issue price [1] - The stock with the largest decline is Wanrun New Energy, which has a closing price that is 77.89% lower than its issue price of 299.88 yuan [1][2] Group 2: Notable Stocks with Significant Discounts - Other notable stocks with significant discounts include: - ST Pava, with a discount of 76.37% from its issue price of 51.88 yuan [1][2] - Chengda Biology, with a discount of 71.00% from its issue price of 110.00 yuan [2] - Tianyi New Materials, with a discount of 64.21% from its issue price of 20.37 yuan [2] Group 3: Industry Performance Metrics - The average issue price earnings ratio for Wanrun New Energy is 75.25 times, significantly higher than the industry average of 19.21 times [1] - ST Pava has an issue price earnings ratio of 93.68 times, compared to the industry average of 29.25 times [1]

Group 1 - The Hang Seng Index rose by 0.68% while the Hang Seng Tech Index fell by 0.24% [1] - Heng Rui Medicine saw a significant increase of over 24% [1] - CanSino Biologics increased by over 10% [1] Group 2 - Ningde Times and Dongfang Zhenxuan both rose by over 6% [1] - Ganfeng Lithium experienced a decline of over 6% [1] - Mixue Group fell by nearly 5% [1]

Group 1 - The core viewpoint of the news highlights a significant rise in virus prevention stocks, particularly in response to the reported cases of Chikungunya fever in Foshan, Guangdong Province [1][2][3] - Notable stock performances include Zhifei Biological, which increased by 16.86%, and Watson Bio, which rose by 13.39%, among others [2] - The total market capitalization of Zhifei Biological is reported at 57.7 billion, while Watson Bio stands at 21 billion [2] Group 2 - As of July 22, Foshan has reported a total of 3,195 confirmed cases of Chikungunya fever, primarily concentrated in the Shunde District [2] - The World Health Organization has issued a warning regarding mosquito-borne diseases, urging countries to prepare for potential outbreaks [3]

Group 1 - The stock of CanSino Biologics (06185.HK) has experienced a significant surge, rising over 12% [1] - The trading volume for CanSino Biologics has exceeded 150 million Hong Kong dollars [1]

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

Group 1 - Tiande Yu achieved a net profit of 1.52 billion yuan in the first half of 2025, a year-on-year increase of 50.89% [1] - Tiande Yu's operating income for the same period was 12.08 billion yuan, reflecting a growth of 43.35% year-on-year [1] - Fule New Materials plans to reduce its shareholding by up to 1.33%, amounting to 376.25 million shares, due to personal funding needs [1] - Jindi Co. signed an industrial project investment contract with a total investment of no less than 1.5 billion yuan [1] Group 2 - Tuo Xin Pharmaceutical intends to invest 10 million yuan in Jiangsu Jinsan Biotechnology, acquiring a 1.75% stake [1] - Pinming Technology expects a net profit of 28 million to 34 million yuan for the first half of 2025, a year-on-year increase of 231.79% to 302.89% [4] - Shuanglin Co. anticipates a net profit of 251 million to 310 million yuan, representing a growth of 1% to 25% year-on-year [7] Group 3 - Kangxino received approval for clinical trials of its trivalent poliovirus vaccine [8] - Bailian Co. signed a land storage compensation contract worth approximately 2 billion yuan [9] - Wukuang Development plans to issue short-term financing bonds and medium-term notes totaling up to 2 billion yuan each [10] Group 4 - Hengxin Life intends to invest 10 million yuan in a targeted equity investment [12] - Hengyin Technology expects a net profit of 13.5 million to 16.2 million yuan, marking a turnaround from losses [14] - *ST Jinglun anticipates a net loss of 19 million to 22 million yuan for the first half of 2025 [15] Group 5 - Baiyun Electric won a bid for a State Grid project worth 164 million yuan [16] - Zhejiang Energy completed a power generation of 788.48 billion kWh in the first half of 2025, a year-on-year increase of 4.48% [17] - Sheneng Co. reported a power generation of 259.51 billion kWh, a decrease of 1.7% year-on-year [19] Group 6 - Hengerd signed a strategic cooperation framework agreement with Tiangong International [21] - Baotai's application for the listing of Golimumab injection has been accepted by the FDA [23] - Yishitong received a government subsidy of 2 million yuan [24] Group 7 - Jinggong Steel signed a contract worth approximately 550 million yuan for the Jeddah Stadium project in Saudi Arabia [26] - Zhongwang Software received a government subsidy of 28 million yuan [27] - Rongxin Culture used idle funds of 100 million yuan to purchase financial products [29] Group 8 - Lingxiao Pump Industry invested 80 million yuan in financial products [31] - China Pacific Insurance reported a total original insurance premium income of 282 billion yuan from its subsidiaries [32] - Kema Technology expects a net profit of 165 million to 175 million yuan, a year-on-year increase of 18.59% to 25.77% [32] Group 9 - Qujiang Cultural Tourism anticipates a net loss of approximately 13 million to 16.9 million yuan [32] - Daoshi Technology expects a net profit of 220 million to 238 million yuan, a year-on-year increase of 98.77% to 115.03% [32] - Baicheng Medicine forecasts a net profit decline of 95.53% to 100% [33] Group 10 - Bertley plans to invest 198 million yuan to establish a partnership for investments in emerging fields [34] - China Merchants Highway announced the resignation of its chairman due to reaching retirement age [35] - Overseas Chinese Town A reported a 29% decrease in contract sales amount in June [36]